Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01727869
Title Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Erlotinib + REGN1400

Cetuximab + REGN1400

REGN1400

Age Groups: adult
Covered Countries USA


No variant requirements are available.